Keith Wong – 2022 ASCO Meeting – Poster Session – Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

This phase 1 study aims to assess the safety and potential of the novel radiotracer 64Cu-Sarcophagine(SAR)-Bombesin (BBN) in the re-staging of recurrent metastatic ER+/PR+/human epidermal growth factor 2 negative (HER2-) breast cancer.

64Cu-SAR-Bombesin is a novel Tracer which appears safe and may have a diagnostic and Theranostic role in patients with metastatic ER+/PR+/HER2- breast cancer, particularly lobular subtype. Further evaluation appears warranted.

Read the abstract >>